Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients

Ethypharm316 enrolled

Overview

The purpose of the study is to assess the efficacy of Xylka® (baclofen) compared to placebo on continuous abstinence rate during 20 weeks of treatment, after withdrawal, in alcohol dependent patients receiving Brenda therapy sessions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

316

Conditions

Alcohol Dependence

Interventions

BaclofenDRUG

Placebo (for baclofen)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients meeting DSM IV(Diagnosis and Statistical Manual of Mental Disorders, 4th edition) criteria for alcohol dependence * Willing to participate in the study and express a desire to achieve the objective of continuous and long term abstinence after withdrawal * Abstinent (last drinking) for a minimum of 3 days and maximum of 14 days * At least one previous abstinence attempt Exclusion Criteria: * Need for a stay at the end of the withdrawal period in a health care and rehabilitation institution specialized in addiction * Need for a heavy psychosocial out of hospital care * History of baclofen intake, by prescription or self medication * Porphyria * Concomitant treatment with one or several drugs for the maintenance of abstinence * Severe renal, cardiac or pulmonary disorder * Epilepsy or history of epilepsy * Concomitant treatment with psychotropic drugs, except antidepressants at stable dose for 2 months, diazepam and oxazepam * Severe psychiatric disease (schizophrenia and bipolar disorder) * Suicidal risk or history of suicide * Clinically significant cognitive disorders * Hepatic encephalopathy * Ongoing dependence or within the last 12 months on other addictive substances (opioid, cocaine, cannabis, other substances or drugs…), excepted tobacco

Locations (38)

Unnamed facility

Outcomes

Primary Outcomes

Continuous abstinence rate in each group (baclofen or placebo) during 20 weeks of treatment, from Day 29 to Day 168.

Time frame: Day 168

Secondary Outcomes

Continuous abstinence rate from the first intake of study treatment (Day 1) to the end of the maintenance dose period (Day 168), i.e. 24 weeks

Time frame: Day 168

Continuous abstinence rate from the first intake of study treatment (Day 1) to the end of 4-week post treatment follow up period (Day 210), i.e. 30 weeks

Time frame: Day 210

Continuous abstinence rate during 20 weeks of treatment (Day 29 to Day 168), according to the severity of alcohol dependence

Time frame: Day 168

Continuous abstinence rate during 20 weeks of treatment (Day 29 to Day 168), according to the level of drinking before withdrawal (Time Line Follow Back calendar/ World Health Organization criteria for risk of consumption)

Time frame: Day 168

Drinking characteristics for patients having a relapse between Day 1 and Day 210

Time to relapse (Day 1 to first drinking day) Time to relapse to first high risk drinking day (\>60g for a male, \> 40g for a female) Percentage of drinking days from Day 1 to Day 210 Mean number of standard drinks per drinking day and classification according to World Health Organization criteria for the risk of consumption Percentage of high risk drinking days during the maintenance period at the target dosage (Day 50 to Day 168) compared to the percentage of high risk drinking days during the preceding 4 weeks of the withdrawal Percentage of drinking days during the maintenance period at the target dosage (Day 50 to Day 168) compared to the percentage of drinking days during the preceding 4 weeks of the withdrawal

Time frame: Day 210

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.